We are live on ! Find out more
RPRX

Repros Therapeutics Inc.
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

56 hedge funds and large institutions have $12.3M invested in Repros Therapeutics Inc. in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more call options, than puts

Call options by funds: $564K | Put options by funds: $342K

3% less funds holding

Funds holding: 5856 (-2)

11% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 18

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

88% less capital invested

Capital invested by funds: $104M → $12.3M (-$91.4M)

Holders
56
Holders Change
-2
Holders Change %
-3.45%
% of All Funds
1.47%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
16
Increased
13
Reduced
16
Closed
18
Calls
$564K
Puts
$342K
Net Calls
+$222K
Net Calls Change
-$9.09M
Name Holding Trade Value Shares
Change
Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$47K +$124K +38,700 New
Renaissance Technologies
27
Renaissance Technologies
New York
$41K -$35.3K -10,987 -24%
Morgan Stanley
28
Morgan Stanley
New York
$35K -$2.23M -695,634 -96%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$33K -$86.1K -26,811 -50%
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
$32K +$83.8K +26,116 New
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$31K -$43.2K -13,452 -35%
AL
32
Airain Ltd
Guernsey
$28K +$73.7K +22,970 New
JP Morgan Chase
33
JP Morgan Chase
New York
$20K +$53.4K +16,643 New
State Street
34
State Street
Massachusetts
$16K
MWAC
35
Mariner Wealth Advisors (Cincinnati)
Ohio
$13K +$35.3K +11,000 New
Creative Planning
36
Creative Planning
Kansas
$12K +$31.8K +9,913 +7,236%
Barclays
37
Barclays
United Kingdom
$10K -$392K -122,221 -93%
CG
38
Cutler Group
California
$9K +$25.9K +8,083 New
Wells Fargo
39
Wells Fargo
California
$7K -$13.5K -4,200 -44%
CLOS
40
Compagnie Lombard Odier SCmA
Switzerland
$7K
BA
41
BlackRock Advisors
Delaware
$5K
BIM
42
BlackRock Investment Management
Delaware
$5K +$372 +116 +3%
PAM
43
Panagora Asset Management
Massachusetts
$5K +$12.3K +3,823 New
UBS Group
44
UBS Group
Switzerland
$4K +$9.56K +2,980 +1,183%
TRCT
45
Tower Research Capital (TRC)
New York
$4K +$10.6K +3,315 New
BFEC
46
Benjamin F. Edwards & Company
Missouri
$3K
Parallax Volatility Advisers
47
Parallax Volatility Advisers
California
$2K -$36.6K -11,415 -88%
LTFS
48
Ladenburg Thalmann Financial Services
Florida
$1K -$3.74K -1,165 -54%
Bank of Montreal
49
Bank of Montreal
Ontario, Canada
$1K -$802 -250 -20%
Citigroup
50
Citigroup
New York
$1K +$305 +95 +8%

RPRX Hedge Fund Activity: Q4 2015 in Review

56 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q4 2015, worth a combined $12.3M — down 88% from $104M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of RPRX and 16 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 13 added.

The largest buyer was Millennium Management, adding an estimated $1.17M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $14.5M sold.

  • 56 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q4 2015, down from 58 in Q3 2015.
  • Funds reported $12.3M of Repros Therapeutics Inc. stock for Q4 2015, down 88% quarter-over-quarter.
  • 16 funds opened new Repros Therapeutics Inc. positions in Q4 2015 and 18 closed out, a net change of -2 holders.
  • The largest Repros Therapeutics Inc. buyer in Q4 2015 was Millennium Management, an estimated $1.17M added.
  • The largest Repros Therapeutics Inc. seller in Q4 2015 was Baker Bros. Advisors, an estimated $14.5M sold.

Based on aggregated 13F filings for Q4 2015.